These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 874748)

  • 21. [The crystallography behavior of carbamazepine under compression pressure].
    Kala H; Haack U; Wenzel U; Zessin G; Pollandt P
    Pharmazie; 1987 Aug; 42(8):524-7. PubMed ID: 3432332
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dissolution properties, solid-state transformation and polymorphic crystallization: progesterone case study.
    Araya-Sibaja AM; Paulino AS; Rauber GS; Campos CE; Cardoso SG; Monti GA; Heredia V; Bianco I; Beltrano D; Cuffini SL
    Pharm Dev Technol; 2014 Nov; 19(7):779-88. PubMed ID: 24032356
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Studies on the crystal forms of pefloxacin: preparation, characterization, and dissolution profile.
    Yadav MR; Shaikh AR; Ganesan V; Giridhar R; Chadha R
    J Pharm Sci; 2008 Jul; 97(7):2637-48. PubMed ID: 17854073
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Kinetic study of the polymorphic transformations of phenylbutazone.
    Matsuda Y; Tatsumi E; Chiba E; Miwa Y
    J Pharm Sci; 1984 Oct; 73(10):1453-60. PubMed ID: 6502498
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization and selective crystallization of famotidine polymorphs.
    Lu J; Wang XJ; Yang X; Ching CB
    J Pharm Sci; 2007 Sep; 96(9):2457-68. PubMed ID: 17518361
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Physical characterization of erythromycin: anhydrate, monohydrate, and dihydrate crystalline solids.
    Allen PV; Rahn PD; Sarapu AC; Vanderwielen AJ
    J Pharm Sci; 1978 Aug; 67(8):1087-93. PubMed ID: 671242
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Physicochemical characterization of the various solid forms of carbovir, an antiviral nucleoside.
    Nguyen NA; Ghosh S; Gatlin LA; Grant DJ
    J Pharm Sci; 1994 Aug; 83(8):1116-23. PubMed ID: 7983595
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of crystal habit on the dissolution behaviour of simvastatin crystals and its relationship to crystallization solvent properties.
    Bukovec P; Benkic P; Smrkolj M; Vrecer F
    Pharmazie; 2016 May; 71(5):263-8. PubMed ID: 27348970
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantitative determination of two polymorphic forms of imatinib mesylate in a drug substance and tablet formulation by X-ray powder diffraction, differential scanning calorimetry and attenuated total reflectance Fourier transform infrared spectroscopy.
    Bellur Atici E; Karlığa B
    J Pharm Biomed Anal; 2015 Oct; 114():330-40. PubMed ID: 26099262
    [TBL] [Abstract][Full Text] [Related]  

  • 30. X-ray structural studies and physicochemical properties of cimetidine polymorphism.
    Shibata M; Kokubo H; Morimoto K; Morisaka K; Ishida T; Inoue M
    J Pharm Sci; 1983 Dec; 72(12):1436-42. PubMed ID: 6663481
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preparation and characterization of a new polymorphic form and a solvate of glibenclamide.
    Hassan MA; Sheikh Salem M; Sallam E; al-Hindawi MK
    Acta Pharm Hung; 1997; 67(2-3):81-8. PubMed ID: 9223758
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of polymorphic ampicillin forms.
    Baraldi C; Tinti A; Ottani S; Gamberini MC
    J Pharm Biomed Anal; 2014 Nov; 100():329-340. PubMed ID: 25194347
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A quantitative model to evaluate solubility relationship of polymorphs from their thermal properties.
    Mao C; Pinal R; Morris KR
    Pharm Res; 2005 Jul; 22(7):1149-57. PubMed ID: 16028016
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Physical characterization of the hydrates of urapidil.
    Botha SA; Caira MR; Guillory JK; Lötter AP
    J Pharm Sci; 1988 May; 77(5):444-51. PubMed ID: 3411469
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Crystallization and transitions of sulfamerazine polymorphs.
    Zhang GG; Gu C; Zell MT; Burkhardt RT; Munson EJ; Grant DJ
    J Pharm Sci; 2002 Apr; 91(4):1089-100. PubMed ID: 11948548
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Physical characterization of two oxyphenbutazone pseudopolymorphs.
    Stoltz M; Lötter AP; Van der Watt JG
    J Pharm Sci; 1988 Dec; 77(12):1047-9. PubMed ID: 3244109
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Changes in crystallinity and solubility on comminution of digoxin and observations on spironolactone and oestradiol.
    Florence AT; Salole EG
    J Pharm Pharmacol; 1976 Aug; 28(8):637-42. PubMed ID: 11314
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Solid state characterization of azelnidipine-oxalic acid co-crystal and co-amorphous complexes: The effect of different azelnidipine polymorphs.
    Pan Y; Pang W; Lv J; Wang J; Yang C; Guo W
    J Pharm Biomed Anal; 2017 May; 138():302-315. PubMed ID: 28237872
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Physicochemical characterization of glybuzole polymorphs and their pharmaceutical properties.
    Otsuka M; Ofusa T; Matsuda Y
    Drug Dev Ind Pharm; 1999 Feb; 25(2):197-203. PubMed ID: 10065353
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Crystal modifications and dissolution rate of piroxicam.
    Lyn LY; Sze HW; Rajendran A; Adinarayana G; Dua K; Garg S
    Acta Pharm; 2011 Dec; 61(4):391-402. PubMed ID: 22202198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.